Search
Publications & Presentationsbreadcrumb separatorPublicationsbreadcrumb separatorClinicalbreadcrumb separator2018
Clinical Publications 2018

1 Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. A Cozzi-Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, J Grarup, H Sambatakou, G Fätkenheuer, I Yust, P Schmid, M Gottfredsson, I Khromova, D Jilich , R Flisiak, J Smidt, B Rozentale, R Radoi, MH Losso, JD Lundgren, A Mocroft on behalf of EuroSIDA.
HIV Med. 2018;19(2):102-117. Abstract

2 Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. A.M. W. Efsen, A. Schultze, R.F. Miller, A. Panteleev, A. Skrahin, D.N. Podlekareva, J.M. Miro, E. Girardi, H. Furrer, M.H. Losso, J. Toibaro, J. A. Caylà, A. Mocroft, J.D. Lundgren, F.A. Post, O. Kirk, for the TB:HIV study in EuroCoord.
J Infect. 2018;76(1):44-54. Abstract

3 The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A for EuroSIDA in EuroCOORD.
HIV Med. 2018;19(2):90-101. Abstract 

4 Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV? A Mocroft, K Laut, P Reiss, J Gatell, V Ormaasen, M Cavassini, V Hadziosmanovic, K Mansinho, C Pradier, M Vasylyev, V Mitsura, L Vandekerckhove, L Ostergaard, A Clarke, O Degen, F Mulcahy, A Castagna, Z Sthoeger, L Flamholc, D Sedláček, I Mozer-Lisewska, JD Lundgren for the EuroSIDA study.
AIDS. 2018;32(2):205-215. Abstract

5 Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis.  P Schuetz, Y Wirz, R Sager, M Christ-Crain, D Stolz, M Tamm, L Bouadma, CE Luyt, M Wolff, J Chastre, F Tubach, K Kristoffersen, O Burkhardt, T Welte, S Schroeder, V Nobre, L Wei, HC Bucher, D Annane, K Reinhart, AR Falsey, A Branche, P Damas, M Nijsten, DW de Lange, RO Deliberato, CF Oliveira, V Maravić-Stojković, A Verduri, B Beghé, B Cao, Y Shehabi, JS Jensen, C Corti, JAH van Oers, A Beishuizen, ARJ Girbes, E de Jong, M Briel, B Mueller.
Lancet Infect Dis. 2018;18(1):95-107. Abstract

6 Abacavir use and risk of recurrent myocardial infarction.Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.
AIDS. 2018;32(1):79-88. Abstract

7 Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort. A Roen, K Laut, A Pelchen-Matthews, E Borodulina, L Caldeira, A Clarke, B Clotet, A d'Arminio Monforte, G Fätkenheuer, JM. Gatell Artigas, IKarpov, A Kuznetsova, G Kyselyova, I Mozer-Lisewska, F Mulcahy, L Ragone, A Scherrer, V Uzdaviniene, L Vandekerckhove, V Vannappagari, L Ostergaard, A Mocroft for the EuroSIDA study
HIV Med. 2018;19(4):252-260. Abstract

8 Long-term Effectiveness of Recommended Boosted PI-Based Antiretroviral Therapy in Europe. Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Parades R, Lundgren JD for the EuroSIDA study. 
HIV Med. 2018;19(5):324-338. Abstract

9 Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.  Hatleberg CI,  Ryom L,  El-Sadr W,  Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d’Arminio Monforte A, Kovari H, Law, M, Lundgren JD, Sabin C, On behalf of the Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.
J Int AIDS Soc. 2018;21(3). Abstract

10 Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. Laut KG, Shepherd L, Radoi R, Karpov I, Parczewski M, Mussini C, Maltez F, Losso M, Chkhartishvili N, Elinav H, Kovari H, Blaxhult A, Zangerle R, Trofimora T, Knysz B, Zilmer K, Kouzovatova E, Staub T, Raben D, Lundgren JD, Mocroft A, Kirk O for the EuroSIDA study.
Eurosurveillance 2018  Volume 23, Issue 21. Article 

11 The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. A Schultze, R Paredes, C Sabin, AN Phillips, D Pillay, N Mackie, A Castagna, D Chadwick, K Falconer, AM Geretti, FA Post, T Hill, O Kirk, A Pozniak, M Nelson, A Tostevin, D Dunn, J Lundgren, A Cozzi-Lepri.
Persistent dispAntivir Ther. 2018;23(2):105-116.  Abstract 

12 Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. L Ryom, JD Lundgren, W El-Sadr, P Reiss, O Kirk, M Law, A Phillips, R Weber, E Fontas, A d’ Arminio Monforte, S de Wit, F Dabis, CI Hatleberg, C Sabin, A Mocroft. On behalf of the D:A:D Study group
Lancet HIV. 2018 Jun;5(6):e291-e300.  Abstract

13 Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation.
IP Lodding , C da Cunha Bang, SS Sørensen, F Gustafsson, M Iversen, N Kirkby, M Perch, A Rasmussen, H Sengeløv, A Mocroft, JD Lundgren.
Open Forum Infect Dis. 2018;5(5) Abstract

14  Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia. IP Lodding, HH Schultz, JU Jensen , N Kirkby, M Perch, C Andersen, JD Lundgren , M Iversen.
Transplantation, 2018; 102(2):326-332. Abstract

15  The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. NE Wareham , A Mocroft, H Sengeløv, C Da Cunha-Bang, F Gustafsson, C Heilmann, M Iversen, NS Kirkby, A Rasmussen, SS Sørensen, JD Lundgren; MATCH in PERSIMUNE study group.
J Cancer Res Clin Oncol. 2018. Abstract

16 Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. L Simonsen, E Higgs , RJ Taylor, D Wentworth, A Cozzi-Lepri, S Pett, DE Dwyer, R Davey, R Lynfield, M Losso, K Morales, MJ Glesby, J Weckx, D Carey, C Lane, J Lundgren; INSIGHT FLU002 and FLU003 Study Groups.
Clin Infect Dis. 2018. Abstract

17 Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma.
L Shepherd, L Ryom, M Law, C Ingrid Hatleberg, S de Wit, A d'Arminio Monforte, M Battegay, A Phillips, F Bonnet, P Reiss, C Pradier, A Grulich, C Sabin, J Lundgren, A Mocroft,
J Natl Cancer Inst. 2018;110(6):598-607.  Abstract

18 Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the D:A:D Study. CI Hatleberg, L Ryom, A d’Arminio Monforte, E Fontas, P Reiss, O Kirk, W El-Sadr, A Phillips, S de Wit, F Dabis, R Weber, M Law, JD Lundgren, C Sabin  On behalf of the Data collection of Adverse events of anti-HIV Drugs (D:A:D) Study Group
HIV Med. 2018;19(9):605-618. Epub 2018 Jul 18. Abstract

19 Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. IP Lodding, A Mocroft, C da Cunha Bang, F Gustafsson, M Iversen, N Kirkby, M Perch, A Rasmussen, H Sengeløv, S Sørensen, JD Lundgren.
Transplant Direct. 2018 May 16;4(6):e355. Abstract

20 Associations between serum albumin and serious non-AIDS events among people living with HIV. A Ronit, CI Hatleberg, L Ryom, F Bonnet, W El-Sadr, P Reiss, R Weber, C Pradier, S De Witt, M Law, A d’Arminio Monforte, J Lundgren, A Mocroft, AN Phillips, C Sabin, for the D:A:D Study group
AIDS. 2018;32(13):1837-1848.  Abstract

21 Body Mass Index and the Risk of serious non-AIDS events and all cause mortality in treated HIV-positive individuals: D:A:D Cohort Analysis
AC Achhra, C Sabin, L Ryom, C Hatleberg, A d’Aminio Monforte, S de Wit, A Phillips, C Pradier, R Weber, P Reiss, W El-Sadr, F Bonnet, A Mocroft, J Lundgren, MG Law for the D:A:D study group
J Acquir Immune Defic Syndr. 2018;78(5):579-588.  Abstract

22 Airflow limitation in people living with HIV and matched uninfected controls. Ronit A, Lundgren J, Afzal S, Benfield T, Roen A, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV infection (COCOMO) study group.
Thorax. 2018;73(5):431-438.  Epub 2018 Jan 13. Abstract

23 Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. L Peters, K Laut, C Resnati, S Del Campo, C Leen, K Falconer, T Trofimova, D Paduta, J Gatell, A Rauch, K Lacombe, P Domingo, N Chkhartishvili, R Zangerle, R Matulionyte, V Mitsura, T Benfield, K Zilmer. I Khromova, J Lundgren, J Rockstroh, A Mocroft for the EuroSIDA study. 
AIDS. 2018;32(14):1995-2004. Abstract 

24 Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. A Pelchen-Matthews, L Ryom, A Borges, S Edwards, C Duvivier, C Stefan, H Sambatakou, K Maciejewska, J Joaquín Portu, J Weber, O Degen, A Calmy, DH Reikvam, D Jevtovic, L Wiese, J Smidt, T Smiatacz, G Hassoun, A Kuznetsova, B Clotet, J Lundgren, A Mocroft for the EuroSIDA study.
AIDS. 2018;32(16):2405-2416.  Abstract

25 Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases.
Nordvig J, Aagaard T, Daugaard G, Brown P, Sengeløv H, Lundgren J, Helleberg M.
Open Forum Infect Dis. 2018 5(10)  Abstract

26 Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. Peters L, Mocroft A. Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K, De Wit S, Rockstroh J, Smidt J, Karpov I, Grzeszczuk A, Haziosmanovic V, Gottfredsson M, Radoi R, Kuzovatova E, Orkin C, Ridolfo AL, Zapirain J, Lundgren J for the EuroSIDA study.
Antivir Ther. 2018;23(5):405-413. Abstract

27 Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. K Laut, L Shepherd, M Gottfredsson, D Sedlacek, B Knysz, J Begovac, R Radoi, B Schmied, N Chkhartishvili, E Florence, M Ristola, G Fätkenheuer, F Mulcahy, P Schmid, E Kuzovatova, D Paduta, J Smidt, P Domingo, J Szlávik,  J Lundgren, A Mocroft, O Kirk on behalf of the EuroSIDA study group
AIDS. 2018;32(18):2807-2819. Abstract 

28 Smoking and accelerated lung function decline in HIV-positive individuals: a secondary analysis of the START Pulmonary Substudy. MacDonald DM, Melzer AC, Collins G, Avihingsanon A, Crothers K, Ingraham NE, Mugerwa H, Ristola M, Shuter J, and Kunisaki KM for the INSIGHT START Pulmonary Substudy Group.
J Acquir Immune Defic Syndr 2018; 79(3):e85-e92. Abstract

29 Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. Caro-Vega, A. Schultze, A.M. W. Efsen, F.A. Post, A. Panteleev, A. Skrahin, J.M. Miro, E. Girardi, D.N. Podlekareva, J.D. Lundgren, j. Sierra-Madero, J. Toibaro, J. Andrade-Villanueva, S. Tetradov, J. Fehr, J. Caylà, M.H. Losso, R.F. Miller, A. Mocroft, O. Kirk, B. Crabtree-Ramírez. 
BMC Infect Dis. 2018;18(1):191. Abstract

30 Automated oxygen control with O2matic® during admission with exacerbation of COPD. Hansen EF, Hove JD, Bech CS, Jensen JS, Kallemose T, Vestbo J.
Int J Chron Obstruct Pulmon Dis. 2018;14;13:3997-4003. Abstract

31 Brief Report: Prevalence of Peripheral Artery Disease Is Higher in Persons Living With HIV Compared With Uninfected Controls. Knudsen AD, Gelpi M, Afzal S, Ronit A, Roen A, Mocroft A, Lundgren J, Nordestgaard B, Sillesen H, Lebech AM, Køber L, Kofoed KF, Nielsen SD.
J Acquir Immune Defic Syndr. 2018; 1;79(3):381-385. Abstract

32 Classification of death causes after transplantation (CLASS): Evaluation of methodology and initial results. Wareham NE, Da Cunha-Bang C, Borges ÁH, Ekenberg C, Gerstoft J, Gustafsson F, Hansen D, Heilmann C, Helleberg M, Hillingsø J, Krohn PS, Lodding IP, Lund TK, Lundgren L, Mocroft A, Perch M, Petersen SL, Petruskevicius I, Rasmussen A, Rossing K, Rostved AA, Sengeløv H, Sørensen VR, Sørensen SS, Lundgren JD
J Acquir Immune Defic Syndr. 2018, 1;79(3):381-385. Abstract

33 Computed tomography quantification of emphysema in people living with HIV and uninfected controls. Ronit A, Kristensen T, Hoseth VS, Abou-Kassem D, Kühl JT, Benfield T, Gerstoft J, Afzal S, Nordestgaard BG, Lundgren JD, Vestbo J, Kofoed KF, Nielsen SD; Copenhagen Comorbidity in HIV Infection (COCOMO) study group.
J Acquir Immune Defic Syndr. 2018, 1;79(3):381-385. Abstract

34 Contemporary protease inhibitors and cardiovascular risk. Lundgren J, Mocroft A, Ryom L.
Curr Opin Infect Dis. 2018; 31(1):8-13. Abstract

35 Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa. Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria , Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.
Lancet HIV. 2018;5(3):e146-e154. Abstract

36 European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summary. De Wit S, Battegay M, D'Arminio Monforte A, Lundgren JD, Oprea C, Antinori A, Bhagani S, Fätkenheuer G, Friis-Moller N, Furrer H, Mussini C; European AIDS Clinical Society.
HIV Med. 2018; 19(2):77-80. Abstract

37 Fluid accumulation during acute kidney injury in the intensive care unit. Berthelsen RE, Perner A, Jensen AK, Jensen JU, Bestle MH.
Acta Anaesthesiol Scand. 2018; 62(6):780-790. Abstract

38 Forced fluid removal in intensive care patients with acute kidney injury: The randomised FFAKI feasibility trial. Berthelsen RE, Perner A, Jensen AK, Rasmussen BS, Jensen JU6, Wiis J, Behzadi MT, Bestle MH.
Acta Anaesthesiol Scand. 2018; 62(7):936-944. Abstract

39 Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. Gelpi M, Afzal S, Lundgren J, Ronit A, Roen A, Mocroft A, Gerstoft J, Lebech AM, Lindegaard B, Kofoed KF, Nordestgaard BG, Nielsen SD.
Clin Infect Dis. 2018;67(4):579-586. Abstract

40 Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. GRyom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, Behrens G, Mallon P, Puoti M, Rauch A, Miro JM, Kirk O, Marzolini C, Lundgren JD, Battegay M; EACS Governing Board.
HIV Med. 2018;19(5):309-315. Abstract

41 HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group. Kowalska JD, Bursa D, Gökengin D, Jilich D, Tomazic J, Vasylyev M, Bukovinowa P, Mulabdic V, Antonyak S, Horban A; ECEE Network Group.
HIV Med. 2018; 19(9):629-633. Abstract

42 HIV infection is independently associated with a higher concentration of alpha-1 antitrypsin. Thudium RF, Lundgren J, Benfield T, Nordestgaard BG, Borges ÁH, Gerstoft J, Nielsen SD, Ronit A; Copenhagen Co-morbidity in HIV Infection (COCOMO) Study Group.
HIV Med. 2018;19(10):745-750. Abstract

43 Hyaluronic Acid Is a Biomarker for Allograft Dysfunction and Predicts 1-Year Graft Loss After Liver Transplantation. Rostved AA, Ostrowski SR, Peters L, Lundgren JD, Hillingsø J, Johansson PI, Rasmussen A.
Transplant Proc. 2018; 50(10):3635-3643. Abstract

44 Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
HIV Med. 2018;19(1):42-48. Abstract

45 In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus. Brummel-Ziedins KE, Gissel M, Neuhaus J, Borges ÁH, Chadwick DR, Emery S, Neaton JD, Tracy RP, Baker JV; INSIGHT SMART, ESPRIT Study Groups.
Res Pract Thromb Haemost. 2018;2(4):708-717. Abstract

46 Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. Itenov TS, Johansen ME, Bestle M, Thormar K, Hein L, Gyldensted L, Lindhardt A, Christensen H, Estrup S, Pedersen HP, Harmon M, Soni UK, Perez-Protto S, Wesche N, Skram U, Petersen JA, Mohr T, Waldau T, Poulsen LM, Strange D, Juffermans NP, Sessler DI, Tønnesen E, Møller K, Kristensen DK, Cozzi-Lepri A, Lundgren JD, Jensen JU; Cooling and Surviving Septic Shock (CASS) Trial Collaboration.
Lancet Respir Med. 2018;6(3):183-192. Abstract

47 No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. Wright EJ, Grund B, Robertson KR, Cysique L, Brew BJ, Collins GL, Poehlman-Roediger M, Vjecha MJ, Penalva de Oliveira AC, Standridge B, Carey C, Avihingsanon A, Florence E, Lundgren JD, Arenas-Pinto A, Mueller NJ, Winston A, Nsubuga MS, Lal L, Price RW; INSIGHT START Neurology Substudy Group.
AIDS. 2018;32(8):985-997. Abstract

48 Prevention of HIV transmission by antiretroviral therapy. Lundgren J, Phillips A.
Lancet HIV. 2018;5(3):e108-e109. Abstract

49 Rigorous Clinical Trial Design in Public Health Emergencies Is Essential. Ellenberg SS, Keusch GT, Babiker AG, Edwards KM, Lewis RJ, Lundgren JD, Wells CD, Wabwire-Mangen F, McAdam KPWJ.
Clin Infect Dis. 2018; 66(9):1467-1469. Abstract

50 Sepsis: Personalized Medicine Utilizing 'Omic' Technologies-A Paradigm Shift? Itenov TS, Murray DD, Jensen JUS.
Healthcare (Basel). 2018;6(3). Abstract

51 Serious Non-AIDS Conditions in HIV: Benefit of Early ART. Lundgren JD, Borges AH, Neaton JD.
Curr HIV/AIDS Rep. 2018;15(2):162-171. Abstract

52 Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group.
J Infect Dis. 2018;217(3):405-412. Abstract

53 Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group.
Lancet HIV. 2018; 5(4):e172-e180. Abstract